UTHR vs VRTX
United Therapeutics vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
UTHR
United Therapeutics
70
Buy
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | UTHR | VRTX |
|---|
| AI Score |
70
|
67
|
| Price |
$538.75
|
$496.21
|
| P/E Ratio |
17.82×
|
28.64×
|
| ROE |
18.8%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
86.1%
|
86.0%
|
| Debt / Equity |
0.00×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.9
|
66.6
|
| Beta |
0.58
|
0.292
|
| Expected Upside |
+4.6%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for UTHR versus VRTX.
UTHR leads by 3 points.
UTHR scores 70/100 (Buy) versus VRTX at 67/100 (Buy).
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 15.0% downside vs 4.6% upside.
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical